The ELISA-measured increase in cerebrospinal fluid tau that discriminates Alzheimer's disease from other neurodegenerative disorders is not attributable to differential recognition of tau assembly forms

Seán T. O'Dowd, Mustafa T. Ardah, Per Johansson, Aleksey Lomakin, George B. Benedek, Kinley A. Roberts, Gemma Cummins, Omar M. El Agnaf, Johan Svensson, Henrik Zetterberg, Timothy Lynch, Dominic M. Walsh

Research output: Contribution to journalArticle

9 Citations (Scopus)


Elevated cerebrospinal fluid concentrations of tau discriminate Alzheimer's disease from other neurodegenerative conditions. The reasons for this are unclear. While commercial assay kits are widely used to determine total-tau concentrations, little is known about their ability to detect different aggregation states of tau. We demonstrate that the leading commercial enzyme-linked immunosorbent assay reliably detects aggregated and monomeric tau and evinces good recovery of both species when added into cerebrospinal fluid. Hence, the disparity between total-tau levels encountered in Alzheimer's disease and other neurodegenerative conditions is not due to differential recognition of tau assembly forms or the extent of degeneration.

Original languageEnglish
Pages (from-to)923-928
Number of pages6
JournalJournal of Alzheimer's Disease
Issue number4
Publication statusPublished - 1 Jan 2013



  • Alzheimer's disease
  • cerebrospinal fluid
  • tau

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this